Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kakinuma, C.
Right arrow Articles by Shibutani, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kakinuma, C.
Right arrow Articles by Shibutani, Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Acute Toxicity of an Anti-Fas Antibody in Mice

Chihaya Kakinuma

Toxicology Laboratory, Mochida Pharmaceutical Co., Ltd., 342 Gensuke, Fujieda, Shizuoka 426-8640, Japan

Kinya Takagaki

Toxicology Laboratory, Mochida Pharmaceutical Co., Ltd., 342 Gensuke, Fujieda, Shizuoka 426-8640, Japan

Takehwo Yatomi

Bioscience Laboratory, Mochida Pharmaceutical Co., Ltd., 1-1-1 Kamiya, Kita-ku, Tokyo 115-8515, Japan

Norio Nakamura

Bioscience Laboratory, Mochida Pharmaceutical Co., Ltd., 1-1-1 Kamiya, Kita-ku, Tokyo 115-8515, Japan

Shigekazu Nagata

Department of Genetics, Osaka University Medical School B3, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Akio Uemura

Bioscience Laboratory, Mochida Pharmaceutical Co., Ltd., 1-1-1 Kamiya, Kita-ku, Tokyo 115-8515, Japan

Yasunori Shibutani

Toxicology Laboratory, Mochida Pharmaceutical Co., Ltd., 342 Gensuke, Fujieda, Shizuoka 426-8640, Japan

By histopathologic examination of various organs in 3 normal strains, C3H/HeN, ICR, and DBA/1J, of mice treated intravenously once with anti-Fas antibody (Jo2), we failed to determine any target organ, except the liver, responsible for the acute lethality induced by the Fas/anti-Fas antibody interaction. However, we could show the presence of Fas-mediated apoptosis in other organs aside from the liver and normal mouse strain differences in susceptibility to anti-Fas antibody. Among these strains, C3H/HeN was the most susceptible to the antibody, followed by ICR and DBA/1J. We observed Fas-mediated apoptosis in the liver, spleen, thymus, lymph nodes, Peyer's patch, intestine, skin, coagulation glands, ovary, uterus, and vagina in all 3 strains and additionally in the epididymides and seminal vesicles in the DBA/1J strain. We also demonstrated that Fas-mediated apoptosis of small lymphocytes in the mantle zone of splenic lymphatic follicles preceded that of the hepatocytes or thymic cells. Since cellular damage was most severe in the liver among all the apoptotic organs in the 3 mouse strains, liver injury induced by anti-Fas antibody is speculated to play a significant role in the death.

Key Words: Anti-Fas antibody • Jo2 • acute toxicity • pathology • apoptosis • mice

Toxicologic Pathology, Vol. 27, No. 4, 412-420 (1999)
DOI: 10.1177/019262339902700404


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. Bagnoli, E. Balladore, E. Luison, P. Alberti, F. Raspagliesi, B. Marcomini, S. Canevari, and D. Mezzanzanica
Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment
Mol. Cancer Ther., February 1, 2007; 6(2): 762 - 772.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
U. McDermott, D. B. Longley, L. Galligan, W. Allen, T. Wilson, and P. G. Johnston
Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer
Cancer Res., October 1, 2005; 65(19): 8951 - 8960.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. E. De Paepe, Q. Mao, M. Embree-Ku, L. P. Rubin, and F. I. Luks
Fas/FasL-mediated apoptosis in perinatal murine lungs
Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L730 - L742.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Hasegawa, X. Cheng, K. Kajino, A. Berezov, K. Murata, T. Nakayama, H. Yagita, R. Murali, and M. I. Greene
Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism
PNAS, April 27, 2004; 101(17): 6599 - 6604.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
S. B. Hooser
Fulminant Hepatocyte Apoptosis In Vivo Following Microcystin-LR Administration to Rats
Toxicol Pathol, September 1, 2000; 28(5): 726 - 733.
[Abstract] [PDF]